Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06473871 · 1 trial · 1 indication
Physician global assessment was performed using the overall opinion question of the POSAS scale. Physicians were asked to rate the severity of the participant's scar compared to normal skin. The overall opinion scale score ranged from 1 (normal skin) to 10 (worst imaginable scar). Within participant treatment difference was assessed between the treatment regimens each participant received.
| Arm | Type | Description |
|---|---|---|
| Group 1 | ACTIVE_COMPARATOR | - |
| Group 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-06473871 | DRUG | Single dose administered by injection four different times |
Inclusion Criteria: * Subjects must have hypertrophic (raised) breast scars from previous surgery * Subjects must be healthy Exclusion Criteria: * Currently pregnant or pregnant during the 6 months, prior to inclusion in the study or breast-feeding. * Presence of history of breast cancer
PF-06473871 is being developed to reduce hypertrophic skin scarring, the raised, thickened scars that can form after surgery. It was studied in adults undergoing revision surgery who were at risk of recurring hypertrophic scars. The program sits in dermatology and is a small molecule therapeutic.
PF-06473871 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the clinical program evaluating the compound for reduction of hypertrophic skin scarring following revision surgery.
PF-06473871 is in Phase 2 development. It is an investigational small molecule and has not been approved for any indication. The Phase 2 trial testing it for reduction of hypertrophic skin scarring has completed, and no trials are currently listed as active.
One Phase 2 trial has been run for PF-06473871: NCT01730339, titled Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery. It enrolled 103 adults, was randomized, double blind, and active controlled, and took place in the United States, Germany, Hungary, and Spain.